Microbiome Metasecretome Protein Database Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a comprehensive database of human gut microbiome proteins that interact with the host, hindering the identification and therapeutic application of microbial proteins as drug candidates for various diseases.
Innovation Solution
A method for generating a database of human microbiome proteins, specifically focusing on those with signal peptides, certain length ranges, and structural features, to identify and synthesize proteins from the metasecretome for potential therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive database of human gut microbiome proteins is generated, then identification of drug candidates is improved, but complexity of the system increases
Solution Approach 1:
The patent segments the complex task of microbiome protein analysis by creating a structured database system that divides proteins into specific categories (secreted proteins, surface proteins, periplasmic proteins) based on signal peptide presence and subcellular localization. This segmentation allows systematic identification of drug candidates without overwhelming complexity.
Solution Approach 2:
The patent performs preliminary actions by pre-processing and annotating microbiome protein sequences with metadata including signal peptide predictions, subcellular localization, and structural features before drug candidate identification. This preliminary structuring of data simplifies subsequent analysis and improves identification efficiency.
2Reliability
If proteins with specific structural features are selected, then therapeutic application potential is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by selecting proteins with specific local structural features such as signal peptides, disulfide bonds, and particular subcellular localizations that are associated with therapeutic potential. This focused selection on specific structural qualities improves reliability while managing manufacturing complexity through targeted criteria.
Solution Approach 2:
The patent changes parameters by establishing specific criteria for protein selection including signal peptide presence, protein length ranges, and structural features. These parameter changes define a manageable subset of proteins with enhanced therapeutic potential, balancing reliability improvement with manufacturing feasibility.
3Quantity of substance
If metasecretome proteins are synthesized and prepared, then drug candidate availability is improved, but production time increases
Solution Approach 1:
The patent performs preliminary actions by predicting signal peptides and annotating protein sequences with localization metadata before synthesis. This pre-processing allows for more efficient production planning and reduces overall production time while maintaining drug candidate availability.
Solution Approach 2:
The patent replaces mechanical/experimental systems with computational methods by using in silico prediction algorithms for signal peptide identification and subcellular localization. This substitution dramatically reduces production time while maintaining the quality and availability of drug candidate proteins.
Data Source
AI summary
The present invention relates to the treatment of diseases relating to proteins of the human microbiome metasecretome and, thus, to microbiome interactions, especially microbiome-host interactions. In particular the present invention relates to a method for identification of secreted peptides and proteins of the human microbiome. The present invention also relates to methods for generating a database of human microbiome metasecretome protein sequences. Furthermore, the present invention relates to a method for preparing a protein of the human microbiome metasecretome as well as to the use of such proteins in medicine.